• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TNF Pharmaceuticals, Inc. - Common Stock (NQ:TNFA)

5.200 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TNF Pharmaceuticals, Inc. - Common Stock

News headline image
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”
September 25, 2025
From Q/C Technologies, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
September 24, 2025
From Q/C Technologies, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 17, 2025
From TNF Pharmaceuticals Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 08, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
September 04, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
September 02, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
August 28, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
August 19, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
June 24, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
May 08, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
April 22, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025
April 16, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
March 17, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
March 05, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
February 25, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
January 29, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
January 15, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
December 19, 2024
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
December 09, 2024
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
October 02, 2024
From TNF Pharmaceuticals, Inc.
Via Business Wire
News headline image
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
August 21, 2024
From TNF Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap